Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group

Abstract

Paclitaxel demonstrates moderate activity in salivary gland tumors of mucoepidermoid and adenocarcinoma histology. The poor response rate in adenoid cystic carcinoma is consistent with prior reports in this chemoresistant histologic subtype.

A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer

“…12 Other cisplatin-based regimens have likewise led to objective responses, although to the best of our knowledge only single studies exist for these other combinations. Although it may slightly increase the chance of an objective tumor response, it is not fully clear that combination therapy offers a therapeutic advantage over therapy with single agents that have documented activity, such as mitoxantrone, 13,14 epirubicin, 15 paclitaxel, 16 and vinorelbine. 17 Thus, the choice of a combination regimen, particularly 1 containing cisplatin, must bear in mind the likelihood of additional toxicities.…”

“…In contrast, the regimen may have promising activity in patients with adenocarcinoma histology, with 3 confirmed objective responses and 3 additional patients demonstrating tumor shrinkage; this differential responsiveness of the different histologic subtypes to various chemotherapeutic agents has been described by others. 16 There are too few patients to draw any conclusions regarding the use of this regimen in patients with the other histologic subtypes. To the best of our knowledge, there are no data available regarding the activity of single-agent carboplatin in patients with advanced salivary gland cancers.…”

Adenoviral mediated transduction of adenoid cystic carcinoma by human TRAIL gene driven with hTERT tumor specific promoter induces apoptosis

“…Unfortunately, overall mortality rates have not changed over the past several decades. 3 Since radiation and chemotherapy are not beneficial for patients with advanced disease, 4 and could also increase the risk of developing a second neoplasm, 5 new treatment strategies for ACC are needed.…”

Suppression of salivary adenoid cystic carcinoma growth and metastasis by ErbB3 binding protein Ebp1 gene transfer

“…1 Curative surgery has failed to reduce the overall mortality rate over the past several decades. 2,3 Radiation and chemotherapy are not beneficial for patients with advanced disease 4,5 and also increase the risk of developing a second neoplasm of the salivary gland. 6 Thus, effective agents for treatment of adenoid cystic carcinoma are urgently needed.…”